# First-line Treatment of Metastatic Pancreatic Cancer With Nab-paclitaxel and Gemcitabine

> **NCT02564146** · PHASE2 · COMPLETED · sponsor: **AIO-Studien-gGmbH** · enrollment: 325 (actual)

## Conditions studied

- Metastatic Pancreatic Cancer
- Adenocarcinoma of the Pancreas

## Interventions

- **DRUG:** nab-paclitaxel and gemcitabine
- **DRUG:** gemcitabine mono and nab-paclitaxel and gemcitabine

## Key facts

- **NCT ID:** NCT02564146
- **Lead sponsor:** AIO-Studien-gGmbH
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12
- **Primary completion:** 2022-03
- **Final completion:** 2022-05
- **Target enrollment:** 325 (ACTUAL)
- **Last updated:** 2022-11-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02564146

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02564146, "First-line Treatment of Metastatic Pancreatic Cancer With Nab-paclitaxel and Gemcitabine". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02564146. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*